Leila Salikhovna Sozaeva

Leila Salikhovna Sozaeva

Auto-generated profile, based on publicly available information

Leila Salikhovna Sozaeva

Endocrinology Research Centre

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
PBPaul Bastard
Paul Bastard
EOElizaveta Orlova
Elizaveta Orlova
LSLeila Sozaeva
Leila Sozaeva
RLRomain Lévy
Romain Lévy
AJAlyssa James
Alyssa James
Michail LionakisMichail Lionakis
Michail Lionakis
Patients with biallelic loss-of-function variants of AIRE suffer from autoimmune polyendocrine syndrome type-1 (APS-1) and produce a broad range of autoantibodies (auto-Abs), including circulating auto-Abs neutralizing most type I interferons (IFNs). These auto-Abs were recently reported to account for at least 10% of cases of life-threatening COVID-19 pneumonia in the general population. We report 22 APS-1 patients from 21 kindreds in seven countries, aged between 8 and 48 yr and infected with SARS-CoV-2 since February 2020. The 21 patients tested had auto-Abs neutralizing IFN-α subtypes and/or IFN-ω; one had anti–IFN-β and another anti–IFN-ε, but none had anti–IFN-κ. Strikingly, 19 patients (86%) were hospitalized for COVID-19 pneumonia, including 15 (68%) admitted to an intensive care unit, 11 (50%) who required mechanical ventilation, and four (18%) who died. Ambulatory disease in three patients (14%) was possibly accounted for by prior or early specific interventions. Preexisting auto-Abs neutralizing type I IFNs in APS-1 patients confer a very high risk of life-threatening COVID-19 pneumonia at any age.

7 November 2022 in Cells
Verified
Journal Article
Open access
PDF file
KKKonstantin Kulebyakin
Konstantin Kulebyakin
Pyotr Tyurin-KuzminPyotr Tyurin-Kuzmin
Pyotr Tyurin-Kuzmin
LSLeila Sozaeva
Leila Sozaeva
NVNikita Voloshin
Nikita Voloshin
MNMikhail Nikolaev
Mikhail Nikolaev
MVMaria Vorontsova
Maria Vorontsova
Parathyroid hormone (PTH) is one of the key regulators of calcium and phosphate metabolism in the body, controlling bone metabolism and ion excretion by the kidneys. At present, attempts to use PTH as a therapeutic agent have been associated with side-effects, the nature of which is not always clear and predictable. In addition, it is known that in vivo impairment of PTH post-receptor signaling is associated with atypical differentiation behavior not only of bone cells, but also of connective tissues, including adipose tissue. In this work, we studied the functional responses of multipotent mesenchymal stromal cells (MSCs) to the action of PTH at the level of single cells. We used MSCs isolated from the periosteum and subcutaneous adipose tissue to compare characteristics of cell responses to PTH. We found that the hormone can activate three key responses via its receptor located on the surface of MSCs: single transients of calcium, calcium oscillations, and hormone-activated smooth increase in intracellular calcium. These types of calcium responses led to principally different cellular responses of MSCs. The cAMP-dependent smooth increase of intracellular calcium was associated with pro-osteogenic action of PTH, whereas phospholipase C dependent calcium oscillations led to a decrease in osteogenic differentiation intensity. Different variants of calcium responses are in dynamic equilibrium. Suppression of one type of response leads to increased activation of another type and, accordingly, to a change in the effect of PTH on cell differentiation.

24 November 2022 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
NNNurana Nuralieva
Nurana Nuralieva
Marina YukinaMarina Yukina
Marina Yukina
LSLeila Sozaeva
Leila Sozaeva
MDMaxim Donnikov
Maxim Donnikov
LKLiudmila Kovalenko
Liudmila Kovalenko
IDIvan Dedov
Ivan Dedov
Autoantibodies against type 1 interferons (IFN-I) are a highly specific marker for type 1 autoimmune polyglandular syndrome (APS-1). Moreover, determination of antibodies to omega-interferon (IFN-ω) and alpha2-interferon (IFN-α2) allows a short-term diagnosis in patients with isolated and atypical forms of APS-1. In this study, a comparison of three different methods, namely multiplex microarray-based, cell-based and enzyme-linked immunosorbent assays for detection of antibodies against omega-interferon and alpha2-interferon, was carried out. A total of 206 serum samples from adult patients with APS-1, APS-2, isolated autoimmune endocrine pathologies or non-autoimmune endocrine disorders, and healthy individuals were analyzed. In the APS-1 patient cohort (n = 18), there was good agreement between the results of anti-IFN-I antibody tests performed by three methods, with 100% specificity and sensitivity for microarray-based assay. Although only the cell-based assay can determine the neutralizing activity of autoantibodies, the microarray-based assay can serve as a highly specific and sensitive screening test to identify anti-IFN-I antibody positive patients.

30 November 2021 in Annals of the Russian academy of medical sciences
Verified
Journal Article
Closed access
PDF file
MVMaria Vorontsova
Maria Vorontsova
KKKonstantin Kulebyakin
Konstantin Kulebyakin
NMNadezhda V. Makazan
Nadezhda V. Makazan
LSLeila S. Sozaeva
Leila S. Sozaeva
Pyotr Tyurin-KuzminPyotr Tyurin-Kuzmin
Pyotr Tyurin-Kuzmin
ТАТюрин-Кузьмин Петр Алексеевич
Тюрин-Кузьмин Петр Алексеевич
Parathyroid hormone (PTH) is a key hormone responsible for regulation of calcium homeostasis in the body. Since the main body calcium depot is bone tissue, PTH has a decisive effect on its homeostasis. In this case, the hormone can activate both bone formation and resorption. Thus, PTH can ensure the conjugation of anabolic and catabolic processes, which is necessary for the renewal of bone tissue, which is had to function under constant mechanical stress. At the same time, the use of PTH in medical practice is rather small, despite its high potential as a basis for the treatment of various pathologies associated with impaired bone homeostasis. Presented review, describes the intracellular signaling cascades and molecular mechanisms that underlie the action of PTH on bone tissue cells, and intracellular signaling cascades are described. A separate section examines the cellular mechanisms of the action of PTH on bone homeostasis, discusses how the effect of the hormone on different types of cells provides an interface between the processes of synthesis and resorption. In addition, the review examines diseases associated with impaired bone homeostasis, as well as the role of PTH and impaired signaling in their etiology.

15 June 2015 in Problems of Endocrinology
Verified
Journal Article
Open access
PDF file
LSL S Sozaeva
L S Sozaeva
Аутоиммунный полигландулярный синдром 1-го типа (АПС 1-го типа) - редкое генетическое заболевание, причиной которого являются мутации в гене AIRE. Наряду с генетическими исследованиями для диагностики заболевания возможно исследование уровня антител к интерферонам 1-го типа, в частности к интерферонам-ω и -α2. Приведен обзор литературы, касающейся интерферонов 1-го типа, антител к ним и патофизиологии процессов, индуцируемых антителами к интерферонам.

23 November 2019 in Problems of Endocrinology
Verified
Journal Article
Open access
VTViktoriya V. Troshina
Viktoriya V. Troshina
NRNatalia Yu. Romanova
Natalia Yu. Romanova
LSLeila S. Sozaeva
Leila S. Sozaeva
ETEkaterina Troshina
Ekaterina Troshina
Autoimmune polyglandular syndrome type 1 (APS-1) is a rare disease with autosomal recessive inheritance and it caused by mutations in the autoimmune regulator (AIRE) gene. This disease has clinical polymorphism that including besides endocrinopathies other organ-specific manifestations and that complicates to diagnose of this condition on time. However, most often APS-1 has a characteristic debut and a certain stage of clinical symptom manifestation. This article describes a case report of an 18-year-old patient with confirmed APS-1, in which the course of disease was erased over a long period of life and didnt meet of clinical criteria for the diagnosis in this syndrome. A high quality of life for such patients is possible with timely, individually selected replacement therapy with subsequent follow-up. It is important to remember the need for screening in risk groups for the formation of clinical forms of APS among the subjects presenting with a single endocrine pathology. The continuity of medical supervision by pediatric and adult endocrinological service physicians must be respected that can be traced on the example of the case from our practice.